LIXTE Biotechnology Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Fair Value of Each Option Award Estimated Assumption

For stock options requiring an assessment of value during the year ended December 31, 2020, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate	0.23% to 0.31	%
Expected dividend yield	0	%
Expected volatility	207.67	%
Expected life	4 to 5 years

For stock options requiring an assessment of value during the year ended December 31, 2019, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate	1.47% to 1.85	%
Expected dividend yield	0	%
Expected volatility	133.01% to 171.87	%
Expected life	5 years

Summary of Stock-based Compensation Costs

A summary of stock-based compensation costs for the years ended December 31, 2020 and 2019 is as follows:

	Years Ended December 31,
	2020		2019

Related parties	$	480,634	$	314,631
Non-related parties		770,715		434,024
Total stock-based compensation costs	$	1,251,349	$	748,655

Summary of Stock Option Activity Including Options Form of Warrants

A summary of stock option activity, including options issued in the form of warrants, during the years ended December 31, 2020 and 2019 is presented below.

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)

Stock options outstanding at December 31, 2018		1,291,667		$	3.498
Granted		133,333			6.228
Exercised		—			—
Expired		(116,667	)		1.926
Stock options outstanding at December 31, 2019		1,308,333			3.648
Granted		200,000			7.140
Exercised		—			—
Expired		(33,333	)		3.000
Stock options outstanding at December 31, 2020		1,475,000		$	4.136		3.09

Stock options exercisable at December 31, 2019		1,308,333		$	3.648
Stock options exercisable at December 31, 2020		1,325,000		$	3.796		2.92

Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Including Options Form of Warrants

The exercise prices of common stock options outstanding and exercisable, including options issued in the form of warrants, at December 31, 2020 are as follows:

Exercise Prices		Options Outstanding (Shares)		Options Exercisable (Shares)

$	0.720		75,000		75,000
$	0.900		50,000		50,000
$	0.960		33,333		33,333
$	1.200		83,333		83,333
$	1.680		66,667		66,667
$	3.000		666,667		666,667
$	6.000		166,667		166,667
$	6.600		50,000		50,000
$	7.140		200,000		50,000
$	12.000		83,333		83,333
			1,475,000		1,325,000